Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes

Schizophrenia Research

Volumn 123, Issue 2-3, 2010, Pages 234-243

  Lin, P I ^a,b   Shuldiner, A R ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Endophenotype; Genome wide association study; Schizophrenia; Type 2 diabetes

Indexed keywords

ADIPONECTIN; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; DOPAMINE; GLUCOSE; NEUROLEPTIC AGENT; OLANZAPINE; PHENOTHIAZINE;

COMORBIDITY; DOPAMINE METABOLISM; DRUG EFFICACY; DRUG SAFETY; EPISTASIS; GENE LOCUS; GENE MAPPING; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SIMILARITY; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE ENVIRONMENT INTERACTION; GLUCOSE METABOLISM; HUMAN; HYPERGLYCEMIA; HYPOTHESIS; LINKAGE ANALYSIS; MUTATIONAL ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SCHIZOPHRENIA; SIDE EFFECT; SOCIOECONOMICS; WEIGHT GAIN; WORKING MEMORY;

ADIPONECTIN; COMORBIDITY; DIABETES MELLITUS, TYPE 2; DOPAMINE; ENDOPHENOTYPES; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GLUCOSE; HUMANS; RISK FACTORS; SCHIZOPHRENIA;

EID: 77957922065     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.08.022     Document Type: Review

References (127)

1. Diagnostic and Statistical Manual of Mental Disorders 1994, American Psychiatric Association, American Psychiatric Press, Wasington, DC, text revised. 4th ed.
2. Ando J., Ono Y., Wright M.J. Genetic structure of spatial and verbal working memory. Behav. Genet. 2001, 31:615-624.
3. Arolt V., Lencer R., Nolte A., Muller-Myhsok B., Purmann S., Schurmann M., Leutelt J., Pinnow M., Schwinger E. Eye tracking dysfunction is a putative phenotypic susceptibility marker of schizophrenia and maps to a locus on chromosome 6p in families with multiple occurrence of the disease. Am. J. Med. Genet. 1996, 67:564-579.
4. Auquier P., Lancon C., Rouillon F., Lader M. Mortality in schizophrenia. Pharmacoepidemiol. Drug Saf. 2007, 16:1308-1312.
5. Avignon A., Monnier L. Insulin sensitivity and stress. Diabetes Metab. 2001, 27:233-238.
6. Baddeley A. Working memory. Science 1992, 255:556-559.
7. Barch D.M. What can research on schizophrenia tell us about the cognitive neuroscience of working memory?. Neuroscience 2006, 139:73-84.
8. Bayoumi R.A., Al Yahyaee S.A., Albarwani S.A., Rizvi S.G., Al Hadabi S., Al Ubaidi F.F., Al Hinai A.T., Al Kindi M.N., Adnan H.T., Al Barwany H.S., Comuzzie A.G., Cai G., Lopez-Alvarenga J.C., Hassan M.O. Heritability of determinants of the metabolic syndrome among healthy Arabs of the Oman family study. Obesity (Silver Spring). 2007, 15:551-556.
9. Beaulieu J.M., Gainetdinov R.R., Caron M.G. The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol. Sci. 2007, 28(4):166-172.
10. Becker K.G., Barnes K.C., Bright T.J., Wang S.A. The genetic association database. Nat. Genet. 2004, 36:431-432.
11. Benton D., Parker P.Y., Donohoe R.T. The supply of glucose to the brain and cognitive functioning. J. Biosoc. Sci. 1996, 28:463-479.
12. Bertolino A., Caforio G., Petruzzella V., Latorre V., Rubino V., Dimalta S., Torraco A., Blasi G., Quartesan R., Mattay V.S., Callicott J.H., Weinberger D.R., Scarabino T. Prefrontal dysfunction in schizophrenia controlling for COMT Val158Met genotype and working memory performance. Psychiatry Res. 2006, 147:221-226.
13. Bilder R.M., Goldman R.S., Robinson D., Reiter G., Bell L., Bates J.A., Pappadopulos E., Willson D.F., Alvir J.M., Woerner M.G., Geisler S., Kane J.M., Lieberman J.A. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am. J. Psychiatry 2000, 157:549-559.
14. Bland R., Markovic D., Hills C.E., Hughes S.V., Chan S.L., Squires P.E., Hewison M. Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in pancreatic islets. J. Steroid Biochem. Mol. Biol. 2004, 89-90:121-125.
15. Bouatia-Naji N., Bonnefond A., Cavalcanti-Proenca C., Sparso T., Holmkvist J., Marchand M., Delplanque J., Lobbens S., Rocheleau G., Durand E., De G.F., Chevre J.C., Borch-Johnsen K., Hartikainen A.L., Ruokonen A., Tichet J., Marre M., Weill J., Heude B., Tauber M., Lemaire K., Schuit F., Elliott P., Jorgensen T., Charpentier G., Hadjadj S., Cauchi S., Vaxillaire M., Sladek R., Visvikis-Siest S., Balkau B., Levy-Marchal C., Pattou F., Meyre D., Blakemore A.I., Jarvelin M.R., Walley A.J., Hansen T., Dina C., Pedersen O., Froguel P. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat. Genet. 2009, 41:89-94.
16. Bourlon P.M., Faure-Dussert A., Billaudel B. The de novo synthesis of numerous proteins is decreased during vitamin D3 deficiency and is gradually restored by 1, 25-dihydroxyvitamin D3 repletion in the islets of langerhans of rats. J. Endocrinol. 1999, 162:101-109.
17. Brahmbhatt S.B., Haut K., Csernansky J.G., Barch D.M. Neural correlates of verbal and nonverbal working memory deficits in individuals with schizophrenia and their high-risk siblings. Schizophr. Res. 2006, 87:191-204.
18. Bresee L.C., Majumdar S.R., Patten S.B., Johnson J.A. Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophr. Res. 2010, 117:75-82.
19. Brkanac Z., Chapman N.H., Matsushita M.M., Chun L., Nielsen K., Cochrane E., Berninger V.W., Wijsman E.M., Raskind W.H. Evaluation of candidate genes for DYX1 and DYX2 in families with dyslexia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2007, 144:556-560.
20. Brown A.S., Susser E.S. Prenatal nutritional deficiency and risk of adult schizophrenia. Schizophr. Bull. 2008, 34:1054-1063.
21. Brzustowicz L.M., Simone J., Mohseni P., Hayter J.E., Hodgkinson K.A., Chow E.W., Bassett A.S. Linkage disequilibrium mapping of schizophrenia susceptibility to the CAPON region of chromosome 1q22. Am. J. Hum. Genet. 2004, 74:1057-1063.
22. Camargo L.M., Collura V., Rain J.C., Mizuguchi K., Hermjakob H., Kerrien S., Bonnert T.P., Whiting P.J., Brandon N.J. Disrupted in Schizophrenia 1 Interactome: evidence for the close connectivity of risk genes and a potential synaptic basis for schizophrenia. Mol. Psychiatry 2007, 12:74-86.
23. Chen W.M., Erdos M.R., Jackson A.U., Saxena R., Sanna S., Silver K.D., Timpson N.J., Hansen T., Orru M., Grazia P.M., Bonnycastle L.L., Willer C.J., Lyssenko V., Shen H., Kuusisto J., Ebrahim S., Sestu N., Duren W.L., Spada M.C., Stringham H.M., Scott L.J., Olla N., Swift A.J., Najjar S., Mitchell B.D., Lawlor D.A., Smith G.D., Ben-Shlomo Y., Andersen G., Borch-Johnsen K., Jorgensen T., Saramies J., Valle T.T., Buchanan T.A., Shuldiner A.R., Lakatta E., Bergman R.N., Uda M., Tuomilehto J., Pedersen O., Cao A., Groop L., Mohlke K.L., Laakso M., Schlessinger D., Collins F.S., Altshuler D., Abecasis G.R., Boehnke M., Scuteri A., Watanabe R.M. Variations in the G6PC2/ABCB11 genomic region are associated with fasting glucose levels. J. Clin. Invest. 2008, 118:2620-2628.
24. Chen, P.C., Lao, C.L., Chen, J.C., 2007. Dual alteration of limbic dopamine D1 receptor-mediated signalling and the Akt/GSK3 pathway in dopamine D3 receptor mutants during the development of methamphetamine sensitization. J. Neurochem. 100(1), 225-241.
25. Chiba M., Suzuki S., Hinokio Y., Hirai M., Satoh Y., Tashiro A., Utsumi A., Awata T., Hongo M., Toyota T. Tyrosine hydroxylase gene microsatellite polymorphism associated with insulin resistance in depressive disorder. Metabolism 2000, 49:1145-1149.
26. Chien I.C., Hsu J.H., Lin C.H., Bih S.H., Chou Y.J., Chou P. Prevalence of diabetes in patients with schizophrenia in Taiwan: a population-based National Health Insurance study. Schizophr. Res. 2009, 111:17-22.
27. Conklin H.M., Curtis C.E., Calkins M.E., Iacono W.G. Working memory functioning in schizophrenia patients and their first-degree relatives: cognitive functioning shedding light on etiology. Neuropsychologia 2005, 43:930-942.
28. Cooper G.D., Pickavance L.C., Wilding J.P., Harrold J.A., Halford J.C., Goudie A.J. Effects of olanzapine in male rats: enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. J. Psychopharmacol. 2007, 21:405-413.
29. Cope N., Harold D., Hill G., Moskvina V., Stevenson J., Holmans P., Owen M.J., O'Donovan M.C., Williams J. Strong evidence that KIAA0319 on chromosome 6p is a susceptibility gene for developmental dyslexia. Am. J. Hum. Genet. 2005, 76:581-591.
30. de Leeuw van Weenen J.E., Parlevliet E.T., Maechler P., Havekes L.M., Romijn J.A., Ouwens D.M., Pijl H., Guigas B. The dopamine receptor D2 agonist bromocriptine inhibits glucose-stimulated insulin secretion by direct activation of the alpha2-adrenergic receptors in beta cells. Biochem. Pharmacol. 2010, 79(12):1827-1836.
31. Di F.M., Lappin J.M., Murray R.M. Risk factors for schizophrenia-all roads lead to dopamine. Eur. Neuropsychopharmacol. 2007, 17(Suppl 2):S101-S107.
32. Dickerson F., Rubalcaba E., Viscidi R., Yang S., Stallings C., Sullens A., Origoni A., Leister F., Yolken R. Polymorphisms in human endogenous retrovirus K-18 and risk of type 2 diabetes in individuals with schizophrenia. Schizophr. Res. 2008, 104:121-126.
33. Dixon L., Weiden P., Delahanty J., Goldberg R., Postrado L., Lucksted A., Lehman A. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr. Bull. 2000, 26:903-912.
34. Dynes J.B. Diabetes in schizophrenia and diabetes in non-psychotic medical patients. Dis. Nerv. Syst. 1969, 30:341-344.
35. Edwards K.L., Newman B., Mayer E., Selby J.V., Krauss R.M., Austin M.A. Heritability of factors of the insulin resistance syndrome in women twins. Genet. Epidemiol. 1997, 14:241-253.
36. Fernandez-Egea E., Bernardo M., Parellada E., Justicia A., Garcia-Rizo C., Esmatjes E., Conget I., Kirkpatrick B. Glucose abnormalities in the siblings of people with schizophrenia. Schizophr. Res. 2008, 103:110-113.
37. Ferrannini E., Haffner S.M., Mitchell B.D., Stern M.P. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia 1991, 34:416-422.
38. Frayling T.M., Timpson N.J., Weedon M.N., Zeggini E., Freathy R.M., Lindgren C.M., Perry J.R., Elliott K.S., Lango H., Rayner N.W., Shields B., Harries L.W., Barrett J.C., Ellard S., Groves C.J., Knight B., Patch A.M., Ness A.R., Ebrahim S., Lawlor D.A., Ring S.M., Ben Shlomo Y., Jarvelin M.R., Sovio U., Bennett A.J., Melzer D., Ferrucci L., Loos R.J., Barroso I., Wareham N.J., Karpe F., Owen K.R., Cardon L.R., Walker M., Hitman G.A., Palmer C.N., Doney A.S., Morris A.D., Smith G.D., Hattersley A.T., McCarthy M.I. A common variant in the FTO gene is associated with body mass index and predisposes to childhood and adult obesity. Science 2007, 316:889-894.
39. Freeman M.S., Mansfield M.W., Barrett J.H., Grant P.J. Heritability of features of the insulin resistance syndrome in a community-based study of healthy families. Diabet. Med. 2002, 19:994-999.
40. García-Tornadú I., Ornstein A.M., Chamson-Reig A., Wheeler M.B., Hill D.J., Arany E., Rubinstein M., Becu-Villalobos D. Disruption of the dopamine d2 receptor impairs insulin secretion and causes glucose intolerance. Endocrinology 2010, 51(4):1441-1450.
41. Gasperoni T.L., Ekelund J., Huttunen M., Palmer C.G., Tuulio-Henriksson A., Lonnqvist J., Kaprio J., Peltonen L., Cannon T.D. Genetic linkage and association between chromosome 1q and working memory function in schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2003, 116:8-16.
42. Gold P.E. Role of glucose in regulating the brain and cognition. Am. J. Clin. Nutr. 1995, 61:987S-995S.
43. Goldman L.S. Medical illness in patients with schizophrenia. J. Clin. Psychiatry 1999, 60(Suppl 21):10-15.
44. Goldman D., Ducci F. Deconstruction of vulnerability to complex diseases: enhanced effect sizes and power of intermediate phenotypes. Sci.World J. 2007, 7:124-130.
45. Goldman-Rakic P.S. Working memory dysfunction in schizophrenia. J. Neuropsychiatry Clin. Neurosci. 1994, 6:348-357.
46. Gottesman I.I., Gould T.D. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 2003, 160:636-645.
47. Gough S.C., O'Donovan M.C. Clustering of metabolic comorbidity in schizophrenia: a genetic contribution?. J. Psychopharmacol. 2005, 19:47-55.
48. Greenwood C.E. Dietary carbohydrate, glucose regulation, and cognitive performance in elderly persons. Nutr. Rev. 2003, 61:S68-S74.
49. Gury C. Schizophrenia, diabetes mellitus and antipsychotics. Encephale 2004, 30:382-391.
50. Haddad P.M. Antipsychotics and diabetes: review of non-prospective data. Br. J. Psychiatry Suppl. 2004, 47:S80-S86.
51. Harold D., Paracchini S., Scerri T., Dennis M., Cope N., Hill G., Moskvina V., Walter J., Richardson A.J., Owen M.J., Stein J.F., Green E.D., O'Donovan M.C., Williams J., Monaco A.P. Further evidence that the KIAA0319 gene confers susceptibility to developmental dyslexia. Mol. Psychiatry 2006, 11(1085-91):1061.
52. Haupt D.W., Newcomer J.W. Hyperglycemia and antipsychotic medications. J. Clin. Psychiatry 2001, 62(Suppl 27):15-26.
53. Hennah W., Tuulio-Henriksson A., Paunio T., Ekelund J., Varilo T., Partonen T., Cannon T.D., Lonnqvist J., Peltonen L. A haplotype within the DISC1 gene is associated with visual memory functions in families with a high density of schizophrenia. Mol. Psychiatry 2005, 10:1097-1103.
54. Hindorff L.A., Sethupathy P., Junkins H.A., Ramos E.M., Mehta J.P., Collins F.S., Manolio T.A. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc. Natl Acad. Sci. USA 2009, 106:9362-9367.
55. Hintze B., Bembenek A., Kuhn-Dymecka A., Wronska A., Wciorka J. Working memory dysfunction in patients suffering from schizophrenia and their first-degree relatives. Psychiatr. Pol. 2004, 38:847-860.
56. Ho B.C., Wassink T.H., O'Leary D.S., Sheffield V.C., Andreasen N.C. Catechol-O-methyl transferase Val158Met gene polymorphism in schizophrenia: working memory, frontal lobe MRI morphology and frontal cerebral blood flow. Mol. Psychiatry 2005, 10(229):287-298.
57. Honey G.D., Fletcher P.C. Investigating principles of human brain function underlying working memory: what insights from schizophrenia?. Neuroscience 2006, 139:59-71.
58. Hong L.E., Mitchell B.D., Avila M.T., Adami H., McMahon R.P., Thaker G.K. Familial aggregation of eye-tracking endophenotypes in families of schizophrenic patients. Arch. Gen. Psychiatry 2006, 63:259-264.
59. Howes O.D., Kapur S. The dopamine hypothesis of schizophrenia: version III-the final common pathway. Schizophr. Bull. 2009, 35:549-562.
60. Hsueh W.C., Mitchell B.D., Aburomia R., Pollin T., Sakul H., Gelder E.M., Michelsen B.K., Wagner M.J., St Jean P.L., Knowler W.C., Burns D.K., Bell C.J., Shuldiner A.R. Diabetes in the Old Order Amish: characterization and heritability analysis of the Amish Family Diabetes Study. Diab. Care 2000, 23:595-601.
61. Jacobsen L.K., Pugh K.R., Mencl W.E., Gelernter J. C957T polymorphism of the dopamine D2 receptor gene modulates the effect of nicotine on working memory performance and cortical processing efficiency. Psychopharmacology (Berl). 2006, 188(4):530-540.
62. Jenkinson C.P., Hanson R., Cray K., Wiedrich C., Knowler W.C., Bogardus C., Baier L. Association of dopamine D2 receptor polymorphisms Ser311Cys and TaqIA with obesity or type 2 diabetes mellitus in Pima Indians. Int. J. Obes. Relat. Metab. Disord. 2000, 24(10):1233-1238.
63. Karlsgodt K.H., Glahn D.C., van Erp T.G., Therman S., Huttunen M., Manninen M., Kaprio J., Cohen M.S., Lonnqvist J., Cannon T.D. The relationship between performance and fMRI signal during working memory in patients with schizophrenia, unaffected co-twins, and control subjects. Schizophr. Res. 2007, 89:191-197.
64. Kremen W.S., Jacobsen K.C., Xian H., Eisen S.A., Eaves L.J., Tsuang M.T., Lyons M.J. Genetics of verbal working memory processes: a twin study of middle-aged men. Neuropsychology 2007, 21:569-580.
65. Kyle U.G., Pichard C. The Dutch Famine of 1944-1945: a pathophysiological model of long-term consequences of wasting disease. Curr. Opin. Clin. Nutr. Metab. Care 2006, 9:388-394.
66. Lehtinen A.B., Newton-Cheh C., Ziegler J.T., Langefeld C.D., Freedman B.I., Daniel K.R., Herrington D.M., Bowden D.W. Association of NOS1AP genetic variants with QT interval duration in families from the Diabetes Heart Study. Diabetes 2008.
67. Lehtovirta M., Kaprio J., Groop L., Trombetta M., Bonadonna R.C. Heritability of model-derived parameters of beta cell secretion during intravenous and oral glucose tolerance tests: a study of twins. Diabetologia 2005, 48:1604-1613.
68. Lencz T., Lambert C., DeRosse P., Burdick K.E., Morgan T.V., Kane J.M., Kucherlapati R., Malhotra A.K. Runs of homozygosity reveal highly penetrant recessive loci in schizophrenia. Proc. Natl Acad. Sci. USA 2007, 104:19942-19947.
69. Li Y., Wu G.D., Zuo J., Meng Y., Fang F.D. Screening susceptibility genes of type 2 diabetes in Chinese population by single nucleotide polymorphism analysis. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2005, 27:274-279.
70. Lindenmayer J.P., Nathan A.M., Smith R.C. Hyperglycemia associated with the use of atypical antipsychotics. J. Clin. Psychiatry 2001, 62(Suppl 23):30-38.
71. Lindenmayer J.P., Czobor P., Volavka J., Citrome L., Sheitman B., McEvoy J.P., Cooper T.B., Chakos M., Lieberman J.A. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am. J. Psychiatry 2003, 160:290-296.
72. Lovestone S., Killick R., Di Forti M., Murray R. Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci. 2007, 30:142-149.
73. Ma L., Hanson R.L., Que L.N., Cali A.M., Fu M., Mack J.L., Infante A.M., Kobes S., Bogardus C., Shuldiner A.R., Baier L.J. Variants in ARHGEF11, a candidate gene for the linkage to type 2 diabetes on chromosome 1q, are nominally associated with insulin resistance and type 2 diabetes in Pima Indians. Diabetes 2007, 56:1454-1459.
74. Matthysse S., Holzman P.S., Gusella J.F., Levy D.L., Harte C.B., Jorgensen A., Moller L., Parnas J. Linkage of eye movement dysfunction to chromosome 6p in schizophrenia: additional evidence. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2004, 128:30-36.
75. McGrath J., Saari K., Hakko H., Jokelainen J., Jones P., Jarvelin M.R., Chant D., Isohanni M. Vitamin D supplementation during the first year of life and risk of schizophrenia: a Finnish birth cohort study. Schizophr. Res. 2004, 67:237-245.
76. Meloni R., Laurent, C., Campion, D., Ben Hadjali, B., Thibaut, F., Dollfus, S., Petit, M., Samolyk, D., Martinez, M., Poirier, M.F., et al., 1995. A rare allele of a microsatellite located in the tyrosine hydroxylase gene found in schizophrenic patients. C. R. Acad. Sci. III 318(7), 803-809.
77. Mills G.W., Avery P.J., McCarthy M.I., Hattersley A.T., Levy J.C., Hitman G.A., Sampson M., Walker M. Heritability estimates for beta cell function and features of the insulin resistance syndrome in UK families with an increased susceptibility to type 2 diabetes. Diabetologia 2004, 47:732-738.
78. Miranda A., Garcia J., Lopez C., Gordon D., Palacio C., Restrepo G., Ortiz J., Montoya G., Cardeno C., Calle J., Lopez M., Campo O., Bedoya G., Ruiz-Linares A., Ospina-Duque J. Putative association of the carboxy-terminal PDZ ligand of neuronal nitric oxide synthase gene (CAPON) with schizophrenia in a Colombian population. Schizophr. Res. 2006, 82:283-285.
79. Murray R.M., Lappin J., Di F.M. Schizophrenia: from developmental deviance to dopamine dysregulation. Eur. Neuropsychopharmacol. 2008, 18(Suppl 3):S129-S134.
80. Myles-Worsley M., Park S. Spatial working memory deficits in schizophrenia patients and their first degree relatives from Palau, Micronesia. Am. J. Med. Genet. 2002, 114:609-615.
81. Nagatsu T. Tyrosine hydroxylase: human isoforms, structure and regulation in physiology and pathology. Essays Biochem. 1995, 30:15-35.
82. Newcomer J.W. Metabolic syndrome and mental illness. Am. J. Manag. Care. 2007, 13:S170-S177.
83. Newcomer J.W., Haupt D.W., Fucetola R., Melson A.K., Schweiger J.A., Cooper B.P., Selke G. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch. Gen. Psychiatry 2002, 59:337-345.
84. Nobel P. D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2003, 116B(1):103-125.
85. Olsson G.M., Hulting A.L., Montgomery S.M. Cognitive function in children and subsequent type 2 diabetes. Diab. Care 2008, 31:514-516.
86. Palmer N.D., Goodarzi M.O., Langefeld C.D., Ziegler J., Norris J.M., Haffner S.M., Bryer-Ash M., Bergman R.N., Wagenknecht L.E., Taylor K.D., Rotter J.I., Bowden D.W. Quantitative trait analysis of T2D susceptibility loci identified from whole genome association studies in the IRAS Family Study. Diabetes 2008, 57:1093-1100.
87. Papanikolaou Y., Palmer H., Binns M.A., Jenkins D.J., Greenwood C.E. Better cognitive performance following a low-glycaemic-index compared with a high-glycaemic-index carbohydrate meal in adults with type 2 diabetes. Diabetologia 2006, 49:855-862.
88. Parasuraman R., Greenwood P.M., Kumar R., Fossella J. Beyond heritability: neurotransmitter genes differentially modulate visuospatial attention and working memory. Psychol. Sci. 2005, 16:200-207.
89. Park S., Holzman P.S. Association of working memory deficit and eye tracking dysfunction in schizophrenia. Schizophr. Res. 1993, 11:55-61.
90. Park S., Holzman P.S., Goldman-Rakic P.S. Spatial working memory deficits in the relatives of schizophrenic patients. Arch. Gen. Psychiatry 1995, 52:821-828.
91. Pascoe L., Tura A., Patel S.K., Ibrahim I.M., Ferrannini E., Zeggini E., Weedon M.N., Mari A., Hattersley A.T., McCarthy M.I., Frayling T.M., Walker M. Common variants of the novel type 2 diabetes genes CDKAL1 and HHEX/IDE are associated with decreased pancreatic beta-cell function. Diabetes 2007, 56:3101-3104.
92. Poulsen P., Levin K., Petersen I., Christensen K., Beck-Nielsen H., Vaag A. Heritability of insulin secretion, peripheral and hepatic insulin action, and intracellular glucose partitioning in young and old Danish twins. Diabetes 2005, 54:275-283.
93. Reaven G.M. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988, 37:1595-1607.
94. Rouillon F., Sorbara F. Schizophrenia and diabetes: epidemiological data. Eur. Psychiatry 2005, 20(Suppl 4):S345-S348.
95. Rusnák, M,. Jeloková, J., Vietor, I., Sabban, E.L., Kvetnanskỳ, R., 1998. Different effects of insulin and 2-deoxy-D-glucose administration on tyrosine hydroxylase gene expression in the locus coeruleus and the adrenal medulla in rats. Brain. Res. Bull. 46(5), 447-452.
96. Ryan C.M., Freed M.I., Rood J.A., Cobitz A.R., Waterhouse B.R., Strachan M.W. Improving metabolic control leads to better working memory in adults with type 2 diabetes. Diab. Care 2006, 29:345-351.
97. Rybakowski J.K., Borkowska A., Czerski P.M., Hauser J. Dopamine D3 receptor (DRD3) gene polymorphism is associated with the intensity of eye movement disturbances in schizophrenic patients and healthy subjects. Mol. Psychiatry 2001, 6:718-724.
98. Rybakowski J.K., Borkowska A., Czerski P.M., Hauser J. Eye movement disturbances in schizophrenia and a polymorphism of catechol-O-methyltransferase gene. Psychiatry Res. 2002, 113:49-57.
99. Saddichha S., Manjunatha N., Ameen S., Akhtar S. Diabetes and schizophrenia - effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia. Acta Psychiatr. Scand. 2008, 117:342-347.
100. Savoy Y.E., Ashton M.A., Miller M.W., Nedza F.M., Spracklin D.K., Hawthorn M.H., Rollema H., Matos F.F., Hajos-Korcsok E. Differential effects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: evidence for the involvement of sympathetic regulation. Schizophr. Bull. 2008.
101. Saykin A.J., Shtasel D.L., Gur R.E., Kester D.B., Mozley L.H., Stafiniak P., Gur R.C. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch. Gen. Psychiatry 1994, 51:124-131.
102. Schaub M.A., Kaplow I.M., Sirota M., Do C.B., Butte A.J., Batzoglou S. A classifier-based approach to identify genetic similarities between diseases. Bioinformatics 2009, 25:i21-i29.
103. Scott L.J., Mohlke K.L., Bonnycastle L.L., Willer C.J., Li Y., Duren W.L., Erdos M.R., Stringham H.M., Chines P.S., Jackson A.U., Prokunina-Olsson L., Ding C.J., Swift A.J., Narisu N., Hu T., Pruim R., Xiao R., Li X.Y., Conneely K.N., Riebow N.L., Sprau A.G., Tong M., White P.P., Hetrick K.N., Barnhart M.W., Bark C.W., Goldstein J.L., Watkins L., Xiang F., Saramies J., Buchanan T.A., Watanabe R.M., Valle T.T., Kinnunen L., Abecasis G.R., Pugh E.W., Doheny K.F., Bergman R.N., Tuomilehto J., Collins F.S., Boehnke M. A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants. Science 2007, 316:1341-1345.
104. Scuteri A., Sanna S., Chen W.M., Uda M., Albai G., Strait J., Najjar S., Nagaraja R., Orru M., Usala G., Dei M., Lai S., Maschio A., Busonero F., Mulas A., Ehret G.B., Fink A.A., Weder A.B., Cooper R.S., Galan P., Chakravarti A., Schlessinger D., Cao A., Lakatta E., Abecasis G.R. Genome-wide association scan shows genetic variants in the FTO gene are associated with obesity-related traits. PLoS Genet. 2007, 3:e115.
105. Sernyak M.J., Gulanski B., Leslie D.L., Rosenheck R. Undiagnosed hyperglycemia in clozapine-treated patients with schizophrenia. J. Clin. Psychiatry 2003, 64:605-608.
106. Sommerfield A.J., Deary I.J., Frier B.M. Acute hyperglycemia alters mood state and impairs cognitive performance in people with type 2 diabetes. Diab. Care 2004, 27:2335-2340.
107. Spelman L.M., Walsh P.I., Sharifi N., Collins P., Thakore J.H. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet. Med. 2007, 24:481-485.
108. Sten-Linder M., Wedell A., Iselius L., Efendic S., Luft R., Luthman H. DNA polymorphisms in the human tyrosine hydroxylase/insulin/insulin-like growth factor II chromosomal region in relation to glucose and insulin responses. Diabetologia 1993, 36:25-32.
109. Thermenos H.W., Seidman L.J., Breiter H., Goldstein J.M., Goodman J.M., Poldrack R., Faraone S.V., Tsuang M.T. Functional magnetic resonance imaging during auditory verbal working memory in nonpsychotic relatives of persons with schizophrenia: a pilot study. Biol. Psychiatry 2004, 55:490-500.
110. Thibaut, F., Ribeyre, J.M., Dourmap, N., Meloni, R., Laurent, C., Campion, D., Ménard, J.F., Dollfus, S., Mallet, J., Petit, M., 1997. Association of DNA polymorphism in the first intron of the tyrosine hydroxylase gene with disturbances of the catecholaminergic system in schizophrenia. Schizophr. Res. 23(3), 259-264.
111. Thonnard-Neumann E. Phenothiazines and diabetes in hospitalized women. Am. J. Psychiatry 1968, 124:978-982.
112. Torkamani A., Topol E.J., Schork N.J. Pathway analysis of seven common diseases assessed by genome-wide association. Genomics 2008, 92:265-272.
113. Tschoner A., Engl J., Rettenbacher M., Edlinger M., Kaser S., Tatarczyk T., Effenberger M., Patsch J.R., Fleischhacker W.W., Ebenbichler C.F. Effects of six second generation antipsychotics on body weight and metabolism - risk assessment and results from a prospective study. Pharmacopsychiatry 2009, 42:29-34.
114. Verma S.K., Subramaniam M., Liew A., Poon L.Y. Metabolic risk factors in drug-naive patients with first-episode psychosis. J. Clin. Psychiatry 2009, 70:997-1000.
115. Vietor, I., Rusnak, M., Viskupic, E., Blazicek, P., Sabban, E.L., Kvetnansky, R., 1996. Glucoprivation by insulin leads to trans-synaptic increase in rat adrenal tyrosine hydroxylase mRNA levels. Eur. J. Pharmacol. 313(1-2), 119-127.
116. Waterworth D.M., Bassett A.S., Brzustowicz L.M. Recent advances in the genetics of schizophrenia. Cell. Mol. Life Sci. 2002, 59:331-348.
117. Wei, J., Ramchand, C.N., Hemmings, G.P., 1995. Association of polymorphic VNTR region in the first intron of the human TH gene with disturbances of the catecholamine pathway in schizophrenia. Psychiatr. Genet. 5(2), 83-88.
118. Wenk G.L. An hypothesis on the role of glucose in the mechanism of action of cognitive enhancers. Psychopharmacology (Berl). 1989, 99:431-438.
119. WHO The ICD10 Classification of Mental and Behavioural Disorders 1993, Diagnostic criteria for research World Health Organization, Geneva.
120. Wolford J.K., Hanson R.L., Kobes S., Bogardus C., Prochazka M. Analysis of linkage disequilibrium between polymorphisms in the KCNJ9 gene with type 2 diabetes mellitus in Pima Indians. Mol. Genet. Metab. 2001, 73:97-103.
121. Wu W., Shang J., Feng Y., Thompson C.M., Horwitz S., Thompson J.R., MacIntyre E.D., Thornberry N.A., Chapman K., Zhou Y.P., Howard A.D., Li J. Identification of glucose-dependant insulin secretion targets in pancreatic beta cells by combining defined-mechanism compound library screening and siRNA gene silencing. J. Biomol. Screen. 2008, 13(2):128-134.
122. Xu B., Wratten N., Charych E.I., Buyske S., Firestein B.L., Brzustowicz L.M. Increased expression in dorsolateral prefrontal cortex of CAPON in schizophrenia and bipolar disorder. PLoS Med. 2005, 2:e263.
123. Xu H., Kellendonk C.B., Simpson E.H., Keilp J.G., Bruder G.E., Polan H.J., Kandel E.R., Gilliam T.C. DRD2 C957T polymorphism interacts with the COMT Val158Met polymorphism in human working memory ability. Schizophr. Res. 2007, 90(1-3):104-107.
124. Yang L.H., Chen T.M., Yu S.T., Chen Y.H. Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells. Pharmacol. Res. 2007, 56:202-208.
125. Zeggini E., Damcott C.M., Hanson R.L., Karim M.A., Rayner N.W., Groves C.J., Baier L.J., Hale T.C., Hattersley A.T., Hitman G.A., Hunt S.E., Knowler W.C., Mitchell B.D., Ng M.C., O'Connell J.R., Pollin T.I., Vaxillaire M., Walker M., Wang X., Whittaker P., Xiang K., Jia W., Chan J.C., Froguel P., Deloukas P., Shuldiner A.R., Elbein S.C., McCarthy M.I. Variation within the gene encoding the upstream stimulatory factor 1 does not influence susceptibility to type 2 diabetes in samples from populations with replicated evidence of linkage to chromosome 1q. Diabetes 2006, 55:2541-2548.
126. Zeitz U., Weber K., Soegiarto D.W., Wolf E., Balling R., Erben R.G. Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J. 2003, 17:509-511.
127. Zheng Y., Li H., Qin W., Chen W., Duan Y., Xiao Y., Li C., Zhang J., Li X., Feng G., He L. Association of the carboxyl-terminal PDZ ligand of neuronal nitric oxide synthase gene with schizophrenia in the Chinese Han population. Biochem. Biophys. Res. Commun. 2005, 328:809-815.